Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: TECH

Bio-Techne Corporation

Healthcare | Biotechnology

Market prices for TECH are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2026)$1.16

Bio-Techne Corporation (NASDAQ: TECH) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 03:06 UTC.

What Bio-Techne Corporation does

Bio-Techne Corporation develops, manufactures and sells life science reagents, instruments and services for research, diagnostics and bioprocessing markets globally. The company operates through two segments: Protein Sciences, which produces biological reagents and analytical tools used in life science research and drug discovery, and Diagnostics and Spatial Biology, which develops diagnostic products and tissue analysis instruments.

Summarized from Bio-Techne Corporation’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (FY2026)$1.16
Return on equity8.63%
Debt/equity0.09

Revenue, margins & earnings

FY2022 Net income: $272MFY2022 Taxes & interest: $25MFY2022 Operating expenses: $460MFY2022 Cost of revenue: $349M$1.11BFY2022FY2023 Net income: $285MFY2023 Taxes & interest: $14MFY2023 Operating expenses: $471MFY2023 Cost of revenue: $367M$1.14BFY2023FY2024 Net income: $168MFY2024 Taxes & interest: $39MFY2024 Operating expenses: $563MFY2024 Cost of revenue: $389M$1.16BFY2024FY2025 Net income: $73MFY2025 Taxes & interest: $29MFY2025 Operating expenses: $688MFY2025 Cost of revenue: $429M$1.22BFY2025FY2026 Net income: $182MFY2026 Taxes & interest: $70MFY2026 Operating expenses: $547MFY2026 Cost of revenue: $416M$1.22BFY2026
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-30
  • 2026-09-30DirectorOption exercise15,940—
  • 2026-09-30DirectorTax withholding-5,562$403.3K
  • 2026-09-30DirectorStock Options (Right to Buy)Option exercise-15,940—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Bio-Techne Corporation do?

Bio-Techne Corporation develops, manufactures and sells life science reagents, instruments and services for research, diagnostics and bioprocessing markets globally.

When did TECH last file with the SEC?

Bio-Techne Corporation's most recent SEC filing on record is a 8-K filed 2026-06-26. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 03:06 UTC. This page is also available as JSON at /api/data?ticker=TECH and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for TECH and 5,000+ tickers.

Create a free account — keep TECH
For your agent
GET /api/data?ticker=TECH

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt